Clinical Roundup In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds January 31, 2025Vol.51 No.04
Clinical Roundup Chemo + immunotherapy achieve higher complete remission rates in DLBCL than either treatment alone, Mount Sinai trial finds January 31, 2025Vol.51 No.04
Clinical Roundup Adjuvant Celebrex may reduce risk of colon cancer recurrence in patients with evidence of ctDNA January 31, 2025Vol.51 No.04
Drugs & Targets FDA approves Enhertu as first HER2-directed therapy for breast cancer January 31, 2025Vol.51 No.04
Drugs & Targets FDA approves Grafapex as preparative regiment for allogeneic hematopoietic stem cell transplantation in AML or MDS January 31, 2025Vol.51 No.04
Drugs & Targets Yunu, WCG collaborate to support clinical trial imaging services January 31, 2025Vol.51 No.04
Conversation with The Cancer LetterReal-world Evidence RWD company documents baseline trends in women’s cancers before Trump’s policy changes January 24, 2025Vol.51 No.03By Claire Marie Porter
White House Rooting out the “illegal and immoral discrimination” of DEI is the first order of business for Trump January 24, 2025Vol.51 No.03By Paul Goldberg
Trials & Tribulations From clinician scientist to nonprofit CEO January 24, 2025Vol.51 No.03By E. Anders Kolb
